A preponderance of carcinogenesis studies in rodents and epidemiologic studies in humans suggests a potential role of dietary fiber in the prevention of colorectal cancer. Recently, wheat bran fiber used as a dietary supplement has been shown to decrease the growth of rectal adenomatous polyps in patients with familial poiyposis; however, few studies of high-risk human populations have been attempted to determine the effects of dietary fiber supplementation on markers of carcinogenesis in the colon or rectum. We have designed a one-arm study to evaluate the effects of dietary supplementation with wheat bran fiber [i.e., 13.5 g/day for 8 wk; after 1 mo, 2 g/day (compliance evaluation period)] on [ ]thymidine into DNA during 1.5-or 24-hour in vitro incubations) by using the median baseline labeling index as a cutoff between high and low values. On the basis of a chi-square test used to identify patients with a statistically significant (P < .001) change, six of the eight patients who initially had high 24-hour outgrowth labeling indices showed a significant decrease in the rectal mucosa biopsy specimens obtained after treatment. An overall 22% decrease was observed in rectal mucosa cell biopsy specimens obtained at study termination (P < .001). Of the eight patients with initially high total [ 3 H]thymidine-labeling indices in crypt organ culture, four had a significant (P < .001) decrease from baseline values, one had a significant increase, and three showed no change following the fiber intervention. The wheat bran fiber dietary supplement of 13.5 g/day was well tolerated by this group of older (54-70 yr) patients. Although the [ 3 H]-thymidine labeling index data suggest that the wheat bran fiber supplement can inhibit DNA synthesis and rectal mucosa cell proliferation in high-risk patients, the results of this small pilot study should not be overinterpreted vis a vis the potential role of wheat bran fiber as a chemopreventive agent for colorectal cancer. Study results should be confirmed in the setting of a randomized double-blinded clinical trial in colorectal cancer patients. Intermediate markers of carcinogenesis should be used as end points. [J Natl Cancer Inst 82: [1280] [1281] [1282] [1283] [1284] [1285] 1990] Considerable research in animals and humans has been performed to evaluate the potential role of dietary fiber in the prevention of colorectal cancer. In a recent review by Greenwald et al. (7) , data from 55 epidemiologic reports involving 40 studies were analyzed for an association between dietary fiber intake and colon cancer incidence. This meta-analysis supported a direct relationship between colon cancer risk and diets low in fiber content. Of the 55 studies, 32 (58%) identified. an inverse relationship between dietary fiber, fiber-rich diets, or other measures of fiber consumption and the risk of colon cancer. Twenty (37%) of these studies showed a statistically significant inverse association between fiber intake and colon cancer incidence (7) .
Metabolic epidemiologic studies have focused on the difference in colon cancer incidence in Scandinavia, other western countries, and African countries (2) (3) (4) (5) (6) . For example, rural Finns were observed to have dietary intakes of total calories and fat similar to intakes of urban New York residents, who have more than a threefold greater incidence of colon cancer. However, the daily dietary fiber intake in rural Finland has been shown to be two times that of New Yorkers (2) . The New York subjects also had higher concentrations of fecal bile acids and lower quantities of dry feces.
In a recent double-blind, placebo-controlled study, DeCosse et al. (7) showed that a daily dietary supplement of 22.5 g of wheat bran fiber can significantly reduce the number of adenomatous polyps in the low sigmoid colon and rectum of patients with familial polyposis. As a follow-up study, we have designed a one-arm, compliance evaluation trial to evaluate the effects of short-term wheat bran fiber dietary supplementation. 
Methods
Patient selection criteria. Criteria for entry in the study included an age of 40 years or older; history of colon or rectal cancer diagnosed and resected after 1980; no evidence of recurrent disease or history of other severe metabolic or life-threatening acute or chronic disease; and adequate dietary intakes of calories and protein, determined by 4 days of dietary records (>80% of the US recommended daily allowance), were required. Patients were excluded if their dietary fiber intake was 30 g/day or greater or if they were on special diets that precluded compliance with study requirements.
Patients were required to be completely ambulatory and capable of ordinary work efforts (performance status 0-1 by Southwest Oncology Group criteria) and to have normal renal and liver function (serum creatinine =£2.0 mg/dL and serum bilirubin =£2.5 mg/dL). This protocol was approved by the University of Arizona Institutional Review Board, and all patients signed informed consent forms prior to study entry.
Prestudy and on-study requirements. For each patient, we obtained a thorough medical history and performed a physical examination prior to study entry. The following tests were performed: complete blood cell and differential white blood cell counts and blood chemistries, including SMA-20 and determinations of levels of magnesium, zinc, copper, and lipids (cholesterol, triglycerides, and high-and low-density lipoproteins), as well as urinalysis. Prior to the 1-month placebo run-in period and at the end of the third month of the study, patients completed an expanded version of the National Cancer Institute Core Dietary Questionnaire (8) , and we obtained 24-hour dietary intake records (on 3 randomly assigned week days and 1 weekend day at study entry over a 1-week period). This expanded version of the questionnaire better assesses fiber intake.
Records contained all foods consumed and their quantities, vitamin and mineral supplements taken, tobacco use, and use of over-the-counter medications and supplements, especially those that could modify stool characteristics or bowel function. A calendar for dietary fiber supplement intake, fiber supplement questionnaire, a compliance assessment record, and a toxicity review form were filled out and collected monthly at each clinic visit for the duration of the study. Additionally, a Health Behavior Questionnaire (9) A daily serving of 13.5 g of wheat bran fiber (1.5 oz of the cereal supplement) was used during the treatment phase of the present study. This serving size was based on results of an earlier intervention trial in a southern Arizona retirement community in which compliant subjects consumed approximately 13 g of All Bran cereal per day for up to 3 months with acceptable compliance and side effects (70).
Fiber intervention trial design. During an initial 1-month compliance evaluation, all patients were placed on a 2.0 g/day low-fiber cereal supplement provided by the Kellogg Co. The patients were unaware of the fiber content of this low-fiber cereal supplement. Following this 1-month compliance run-in period, all patients were given 13.5 g of wheat bran fiber supplement daily for 8 additional weeks. The All Bran was formulated to look similar to the low-fiber supplement used during the initial 1-month phase of the study. Both daily fiber supplements had similar volume, appearance, and taste. They were distributed in individual unmarked packages to all study participants monthly at each clinic visit. Instructions on building up tolerance to wheat bran fiber intake through small frequent intakes during the first week on low-fiber supplements and during the first week on high-fiber supplements were given to all patients.
Laboratory research procedures.
At the end of the initial 1-month period on the low-fiber cereal supplement and at the end of the 2-month period on high-fiber daily cereal supplement, each patient underwent sigmoidoscopy for the purpose of obtaining multiple biopsy specimens of the rectal mucosa. Patients were prepared for these procedures without cathartics and received only a mild enema of normal saline (0.5 mol/L) prior to removal of up to eight superficial biopsy specimens taken from flat mucosa of the rectum, 8-12 cm above the level of the anal verge. Five of these biopsy specimens were processed for [ /mL ), amphotericin B (5 (ig/mL), penicillin (250 (ig/mL), streptomycin (100 n-g/mL), chloramphenicol (150 p-g/mL), gentamicin (100 jj-g/mL), and bovine serum albumin (1.4 mg/mL) (Sigma Chemical Co., St. Louis, Mo) plus 1 mL each of hyaluronidase (300 U/mL), neuraminidase (4 U/mL), and collagenase (600 U/mL). Digestion was carried out at room temperature on a blood rotor for 1 hour. The digest was then washed three times and cell pellets were resuspended in an appropriate volume of growth medium (NCTC 168; Hazelton; Lenexa, Kan) plus 0.1 units of insulin, 1 |ig/mL of hydrocortisone, 50 jig/mL of epidermal growth factor, 1 x 10~7 M of selenous acid, 8 x 10~9 M of sodium deoxycholate, 5 |xg/mLof pentagastrin, 1 X 10~4 M of ethanolamine, 1 X 10~4 M of phosphoethanolamine, 50 mg/mL of gentamicin (Sigma Chemical Co.), and 15% fetal bovine serum. Aliquots of cell suspension were then placed onto 0.1% gelatin-coated, 35-mm tissue-culture dishes and allowed to adhere for 45 minutes at 37 °C in 5% CO 2 as described previously by Buset et al. (11) . One milliliter of growth medium containing [ A kappa statistic was used to assess the degree of agreement in the classification of significant difference between the [ 3 H]thymidine-labeling index for crypt organ culture and that for outgrowth culture (16) . A series of quality-control studies were completed to determine the reproducibility of the [ 3 H]thymidinelabeling index procedures (17) . The results of these studies, which involved more than 100 subjects, revealed that (a) counting at least 20 crypts per rectal mucosa biopsy specimen yields a 95% confidence limit around the calculated labeling index within 1.5% of the estimated mean, (b) intraobserver variability between two labeling index determinations was 0.5% (P = .35, paired Mest), and (c) interbiopsy site variability between labeling index determinations was 0.6% (P = .4, paired Mest).
Results
Patient characteristics. Between January and November 1988, 17 patients (11 females and six males) with a history of colon or rectal cancer were registered in this trial. The median age of the patients was 70 years (range, 54-78). All patients were white and 65% were college educated.
Of the 17 patients, 15 had resection for colon cancer and two had resection for rectal cancer. The cancer diagnosis had been made between 12 and 48 months prior to trial registration in 14 patients and between 5 and 8 years before registration in three patients. Five patients had Astler-Coller-Duke's stage C cancers (Cl, two patients; C2, three patients); seven patients had stage B cancers (Bl, four patients; B2, three patients); and five patients had stage A cancers (Al, one patient; A2, four patients).
Dietary data. For the 11 females and six males, the average daily intakes of fiber from all dietary sources, based on food records from 4 random days at the start of the study, were 19 ± 7.7 and 20.6 ± 7.7 g, respectively. Mean elemental calcium intake was slightly greater than 1 g/day in females (1,037 ± 299 mg) and somewhat lower in males (887 ± 362 mg). Three of the 11 females and none of the males consumed high-fiber breakfast cereals before entry in the study.
The cumulative average compliance level for supplemental fiber intake was 97.6% in 16 of the 17 subjects. One subject consumed 50%-75% of the predicted daily fiber supplement for approximately 10 days during the study and then achieved good compliance for the majority of the 8-week high-fiber supplementation.
Shown in table 2 are daily intakes of selected nutrients for the trial subjects estimated from the Food-Frequency Questionnaire during treatment with the high-fiber supplement. Baseline values were recorded prior to the 1-month compliance evaluation for the 11 females and 6 males in the study. In most cases, absolute increases were observed between study entry and study completion in the daily intakes of total calories, protein, carbohydrate, fat, and calcium; however, percents of calories for the macronutrients were not increased over baseline values. The total dietary fiber intake in grams per day, including the supplemental cereal fiber, increased significantly (P = .02 in males and P = .04 in * Values = mean ± SD. % kcal = % of total energy from nutrients per day.
t Baseline values were recorded prior to initial 1-mo compliance evaluation of the 11 females and six males in the study.
females according to a one-tailed /-test) between study entry and completion. The absolute intake of fiber from grains was somewhat less than the 13.5 g/day provided by the wheat bran fiber supplement because three female study subjects substituted storebought high-fiber cereals for the wheat bran supplement. Toxicity evaluation. The frequency and severity of gastrointestinal, constitutional, and clinically evident toxic effects of the wheat bran fiber dietary supplement were rated on a scale of 0-3 (0 = none, 1 = mild, 2 = moderate, and 3 = severe). Patients who experienced moderate or severe toxic effects of any type were evaluated for removal from the study. Toxicity monitoring was carried out at the monthly clinic visit and data are shown in figure 1. There were 55 assessments of possible toxic effects in the 17 patients; no toxicity was found in more than 90% of the assessments, and no patient was removed from the study. Mild diarrhea was noted in 2% of the assessments. The only moderate degree of toxicity registered was intestinal gas, which was noted in less than 10% of assessments. No significant change was observed in any of the blood tests, including serum chemistries and blood cell counts.
24-Hour outgrowth culture data. After 2 months of wheat bran fiber supplementation in the 16 patients who had 24-hour outgrowth cultures taken at entry to the study, the mean number of outgrowths per biopsy specimen was 11.6 ± 7.8 SD. Calculations using this value yielded an average of 2,695 ± 1,272 SD cells per specimen and an average of 431 ± 351 SD cells per outgrowth. The cellular response to the 13.5-g/day wheat bran fiber supplement was evaluated statistically in each patient by comparing the baseline [ 3 H]thymidine-labeling indices to values for rectal biopsy specimens obtained 2 months after treatment. To be considered a significant response, the on-treatment labeling index had to be decreased or increased by sufficient magnitude, compared with the baseline value, to permit computation of a P value (13) less than .001. The labeling index was significantly decreased in nine of the 16 patients who could be evaluated, increased significantly in one patient, and unchanged in six patients. One patient could not be evaluated because of a malfunction of the incubator following the second rectal biopsy (table 1) .
The data from the [ 3 H]thymidine-labeling index of the 24-hour outgrowth were categorized further according to initially low versus initially high baseline values. The median baseline labeling index (8.9%) was used as a cutoff between high and low values. Six of the eight patients who had initially high baseline labeling indices showed a significant decrease (P < .001) in the rectal mucosa biopsy specimens obtained during the second month of fiber treatment. Of the eight patients with initially low baseline labeling indices, three showed a significant decrease, one showed a significant increase, and the four remaining patients showed no significant change.
As shown in table 3, there was an overall 22% decrease in the 24-hour outgrowth [ 3 H]thymidine-labeling index following 2 months of dietary supplementation with 13.5 g/day of wheat bran fiber in the rectal mucosa biopsy specimens obtained from the 16 patients who could be evaluated. This change was highly significant (/>< .001).
Crypt organ culture data. Thirty-four biopsy specimens from the 17 patients were evaluated. There was an average of 32 crypts per biopsy specimen. The average crypt column had 44.8 cells (average, 89.6 cells per crypt) and an average of 2,867 cells were counted per biopsy specimen. Again, the cellular response to the 13.5-g/day wheat bran fiber supplement was evaluated statistically in each patient by comparing the baseline to 3-month •Values = mean ± SD. Wheat bran fiber supplementation (13.5 g/day) was given for 8 wk. LIi = labeling index at baseline; LI 2 = labeling index after 8 wk of wheat bran fiber supplementation.
t Paired /-test.
The labeling index was unchanged in nine of the 17 patients, significantly decreased in five patients, and significantly increased in three patients (table 1) . As shown in table 3, no significant change was observed from baseline values for the mean labeling index following 2 months of wheat bran fiber supplementation in the 17 patients.
Patients were categorized further as having initially low or initially high labeling indices through the use of the median baseline labeling index (7.8%) as a cutoff between high and low values. Of the eight patients with initially high total labeling indices, four had a significant decrease, one had a significant increase, and three showed no change following the 2-month wheat bran fiber intervention. Of the nine patients who had an initially low labeling index, one showed a significant decrease, two showed a significant increase, and six showed no change.
Shown in table 4 are the individual [ The rectal mucosa biopsy specimens from five patients showed a significant decrease from baseline in response to the fiber supplementation in both culture systems. There was no change in either crypt organ culture or 24-hour outgrowth culture labeling indices in six patients. Three patients whose rectal mucosa biopsy specimens had a significant decrease in 24-hour outgrowth 
Discussion
The results of this study suggest that a wheat bran fiber dietary supplement of 13.5 g/day for 2 months can inhibit DNA synthesis and epithelial cell proliferation within the rectal mucosa crypts of patients at high risk for recurrence of colorectal cancer. We used stringent statistical criteria for determining whether the [ 3 H]thymidine-labeling index in rectal epithelial cells was significantly changed from the baseline (i.e., before any wheat bran fiber supplement was taken) value (P < .001) in any one study subject. A combination of [ The wheat bran fiber dietary supplement of 13.5 g/day was well tolerated by this group of older patients with previous resection for colorectal cancer. The major toxic effect was flatulence, which was mild in more than 90% of patient assessments. The only other significant fiber-related toxic effect was mild diarrhea, noted in 1 %-2% of assessments. No evidence that fiber supplementation caused hypocalcemia or other significant blood chemistry changes was found. Whether this level of fiber supplementation will be tolerated for an extended period must be tested in a more prolonged study: In such a trial, the monitoring of loss of minor nutrients and loss of bone density will be important, since wheat bran fiber can chelate and subsequently enhance excretion of calcium and other cations (18, 19) .
For our study, we selected a group of patients at high risk for colorectal cancer recurrence. As previously demonstrated by Lipkin et al. (20) and Terpstra et al. (21) , there appears to be a hierarchy of risk for colon cancer in relation to proliferation rates of epithelial cells lining colorectal mucosa crypts. These investigators have shown the [ 
